XML 11 R2.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
$ in Thousands
Sep. 30, 2025
Dec. 31, 2024
ASSETS    
Cash and cash equivalents $ 3,458 $ 40,437
Accounts receivable 538 407
Related party note receivable from MiNK Therapeutics, Inc. 5,725  
Prepaid expenses 885 2,315
Assets held for sale 122,149 0
Other current assets 1,195 2,415
Total current assets 133,950 45,574
Property, plant and equipment, net of accumulated amortization and depreciation of $47,166 and $72,553 at September 30, 2025 and December 31, 2024, respectively 15,987 120,087
Operating lease right-of-use assets 8,027 27,308
Goodwill 24,092 24,092
Acquired intangible assets, net of accumulated amortization of $17,240 and $16,986 at September 30, 2025 and December 31, 2024, respectively 3,122 3,376
Equity method investment in MiNK Therapeutics, Inc. 30,482 0
Other long-term assets 3,188 5,834
Total assets 233,891 226,271
LIABILITIES AND STOCKHOLDERS' DEFICIT    
Current portion, long-term debt 10,610 2,698
Current portion, liability related to sale of future royalties and milestones 103,047 111,978
Current portion, deferred revenue 45 31
Current portion, operating lease liabilities 1,113 2,446
Accounts payable 85,289 61,470
Accrued liabilities 31,752 34,961
Liabilities held for sale 54,566 0
Other current liabilities 710 7,817
Total current liabilities 287,132 221,401
Long-term debt, net of current portion 23,599 30,473
Liability related to sale of future royalties and milestones, net of current portion 192,126 224,389
Deferred revenue, net of current portion 1,143 1,143
Operating lease liabilities, net of current portion 10,383 54,551
Other long-term liabilities 376 738
Commitments and contingencies
STOCKHOLDERS" DEFICIT    
Common stock, par value $0.01 per share; 800,000,000 shares authorized; 32,814,429 and 23,634,670 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively 329 236
Additional paid-in capital 1,899,281 1,857,662
Accumulated other comprehensive loss (1,560) (1,398)
Accumulated deficit (2,172,187) (2,182,880)
Total stockholders' deficit attributable to Agenus Inc. (274,137) (326,380)
Non-controlling interest (6,731) 19,956
Total stockholders' deficit (280,868) (306,424)
Total liabilities and stockholders' deficit 233,891 226,271
Related Parties [Member]    
ASSETS    
Related party note receivable from MiNK Therapeutics, Inc. 5,725 0
Due from related parties (MiNK Therapeutics, Inc.) 15,043 0
Series A-1 convertible preferred stock [Member]    
STOCKHOLDERS" DEFICIT    
Series A-1 convertible preferred stock; 31,620 shares designated, issued, and outstanding at September 30, 2025 and December 31, 2024; liquidation value of $34,263 at September 30, 2025 $ 0 $ 0